

Paul Gougis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8648069/publications.pdf>

Version: 2024-02-01

14
papers

281
citations

1040018

9
h-index

1058452

14
g-index

16
all docs

16
docs citations

16
times ranked

419
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Annual Review of Pharmacology and Toxicology, 2021, 61, 85-112.	9.4	50
2	Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. European Heart Journal, 2021, 42, 3915-3928.	2.2	38
3	Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. JNCI Cancer Spectrum, 2019, 3, pkz055.	2.9	34
4	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. European Journal of Cancer, 2021, 143, 55-63.	2.8	32
5	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmunity Reviews, 2021, 20, 102729.	5.8	26
6	Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. European Respiratory Journal, 2020, 55, 2000038.	6.7	19
7	Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. Archives of Cardiovascular Diseases, 2019, 112, 699-712.	1.6	18
8	Potential cytochrome P450-mediated pharmacokinetic interactions between herbs, food, and dietary supplements and cancer treatments. Critical Reviews in Oncology/Hematology, 2021, 166, 103342.	4.4	17
9	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113968.	2.8	15
10	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Critical Reviews in Oncology/Hematology, 2019, 141, 112-124.	4.4	11
11	Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?. European Journal of Cancer, 2020, 136, 1-3.	2.8	9
12	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. Joint Bone Spine. 2020;87:191-193. Joint Bone Spine, 2021, 88, 105074.	1.6	5
13	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3758.	3.7	4
14	No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC. Cancers, 2022, 14, 3080.	3.7	0